Download original image
Fig. 4. Western blot of mitogen-activated protein kinase (MAPK) signaling and p53. Representative immunoblots of phosphorylated extracellular signal-regulated kinase1/2 (p-ERK1/2; ~44 and ~42 kDa) (A), c-jun-NH2-terminal kinase1/2 (p-JNK1/2; ~46 and ~54 kDa) (B), and phosphorylated p38 (p-p38; ~38 kDa) (C), and p53 (D). The expression levels of p-ERK2/total ERK2 (A), p-JNK1/2/total JNK1/2 (B), and p-p38/total p38 (C) in the SCI+alendronate 1 mg/kg-treated group decreased significantly compared with the SCI+vehicle-treated group. The level of p53 protein was also significantly reduced (D) compared with the SCI+vehicle group. *p<0.05; **p<0.01; ***p<0.001 vs. normal control. #p<0.05; ##p<0.01 vs. SCI+vehicle-treated group. N, normal control; S, sham control; V, SCI+vehicle-treated group; 1, SCI+alendronate 1 mg/kg-treated group.
Exp Neurobiol 2022;31:54~64
© Exp Neurobiol